Mast Therapeutics Inc (MSTX) 0.57 $MSTX
Technical Coverage on Biotech Stocks - Arena Pharma, XOMA, Dyax, Mast Therapeutics, and Tekmira Pharma
PR Newswire - Fri Jan 02, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), XOMA Corporation (NASDAQ: XOMA), Dyax Corporation (NASDAQ: DYAX), Mast Therapeutics Inc. (NYSE MKT: MSTX), and Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 31, 2014, the NASDAQ Composite ended at 4,736.05, down 0.87%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 17,823.07, and the S&P 500 closed at 2,058.90, down 1.03%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 791.97, down 0.98%, while the index has advanced 7.03% in the previous three months. Register for your complimentary reports on these five stocks at:
MSTX: 0.57 (+0.01), TKMR: 14.76 (-0.39), ARNA: 3.59 (+0.12), DYAX: 14.11 (+0.05), XOMA: 3.55 (-0.04)
Wall St. Deal Watch: New Research on VSE, Alexion, LCNB Corp., Lime Energy and Mast Therapeutics
PR Newswire - Fri Jan 02, 7:30AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including VSE (NASDAQ: VSEC), Alexion (NASDAQ: ALXN), LCNB Corp. (NASDAQ: LCNB), Lime Energy (NASDAQ: LIME), and Mast Therapeutics (NYSEMKT: MSTX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
VSEC: 68.58 (+2.68), MSTX: 0.57 (+0.01), LCNB: 14.87 (-0.20), LIME: 2.89 (-0.04), ALXN: 186.60 (+1.57)
Mast Therapeutics To Host Corporate Conference Call
PR Newswire - Tue Dec 30, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that it will hold a conference call at 8am Eastern Time, 5am Pacific Time on Tuesday, January 6, 2015. The Company intends to provide an update on EPIC, its pivotal phase 3 study of its lead product candidate vepoloxamer (MST-188) in sickle cell disease, which the Company continues to expect will complete enrollment by the end of 2015, and anticipated clinical and business milestones for 2015.
MSTX: 0.57 (+0.01)
Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/znzbgg/congestive_heart) has announced the addition of the "Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - Aastrom Biosciences - Johnson & Johnson - AstraZeneca - Athersys - GlaxoSmithKline - Gilead Sciences - Merck & Co - Bioheart - Neurocrine Biosciences - Acorda Therapeutics - Les Laboratoires Servier - Bayer - Celladon - IntelGenx - Mesoblast - Palatin Technologies - Cardio3 BioSciences - La Jolla Pharmaceutical - Mast Therapeutics - NeoStem - Cytomedix - Torrent Pharmaceuticals - Juventas Therapeutics - Protemix Corporation - AngioDesign - Cardioxyl Pharmaceuticals - Innopharmax - QUANTUM GENOMICS - ARCA biopharma For more information visit http://www.researchandmarkets.com/research/zn...tive_heart
JNJ: 104.52 (-0.05), NBIX: 22.84 (+0.50), MSTX: 0.57 (+0.01), GILD: 94.91 (+0.65), MRK: 57.19 (+0.40), PTN: 0.80 (+0.07), GSK: 42.37 (-0.37), BMY: 59.51 (+0.48), ACOR: 40.51 (-0.36)
Mast Announces Plans For Development Of Vepoloxamer (MST-188) In Heart Failure
PR Newswire - Tue Dec 09, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today provided details of its plan to develop vepoloxamer (MST-188), its lead product candidate, in heart failure.
MSTX: 0.57 (+0.01)
Actelion submits MAA for pulmonary hypertension drug
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 2:36PM CST
MSTX: 0.57 (+0.01), GILD: 94.91 (+0.65), UTHR: 127.73 (-1.76), GSK: 42.37 (-0.37), ARNA: 3.59 (+0.12)
Technical Snapshot on Biotech Stocks - Keryx Biopharma, Dyax, Mast Therapeutics, Cubist Pharma, and Intrexon
PR Newswire - Mon Dec 01, 7:30AM CST
Investor-Edge has initiated coverage on the following equities: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Dyax Corporation (NASDAQ: DYAX), Mast Therapeutics Inc. (NYSE MKT: MSTX), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and Intrexon Corporation (NYSE: XON). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, November 28, 2014, the NASDAQ Composite ended at 4,791.63, up 0.09%, the Dow Jones Industrial Average finished the day flat at 17,828.24, and the S&P 500 closed at 2,067.56, down 0.25%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 803.65, up 0.58%, with the index also advancing 8.95% in the previous three months. Register for your complimentary reports on these five stocks at:
CBSTZ: 0.06 (+0.02), MSTX: 0.57 (+0.01), CBST: 100.76 (+0.11), XON: 26.11 (-1.42), DYAX: 14.11 (+0.05), KERX: 14.34 (+0.19)
Mast Therapeutics To Present At The 26th Annual Piper Jaffray Healthcare Conference On December 3rd
PR Newswire - Wed Nov 26, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the 26th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 9:00 a.m. Eastern time in the Rutherford Salon at The New York Palace Hotel in New York City.
MSTX: 0.57 (+0.01)
Highline Research Advisors Initiates on Mast Therapeutics with a Buy Rating
Thomson Reuters ONE - Wed Nov 19, 12:08PM CST
SAN FRANCISCO - November 19, 2014 - Highline Research Advisors, LLC, a Merriman Capital, Inc. Financial Entrepreneur Platform participant announced today that research analyst Michael Higgins has initiated equity research coverage of Mast Therapeutics (AMEX: MSTX) with a Buy rating and a $3.00 price target.
MSTX: 0.57 (+0.01)
New Data From Nonclinical Heart Failure Study To Be Presented At American Heart Association Conference
PR Newswire - Wed Nov 19, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that data from MST-188 (vepoloxamer), its lead product candidate, will be featured at the American Heart Association (AHA) Scientific Sessions 2014. Data will be presented as a poster during the session "Heart Failure Pharmacology: From the Membrane to the Mitochondria." The AHA conference is being held at the McCormick Place Convention Center in Chicago through November 19.
MSTX: 0.57 (+0.01)
Mast Therapeutics To Present MST-188 Data At 2014 American Society Of Hematology Conference
PR Newswire - Mon Nov 17, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that it will be presenting data from an ex vivo study of MST-188 (vepoloxamer), its lead product candidate, at the 56th Annual Meeting of the American Society of Hematology (ASH) taking place December 6 - 9, 2014 in San Francisco, California. The abstract entitled "Pro-coagulant Actions of Circulating Microparticles in Sickle Cell Anemia and Sepsis Associated Coagulopathy and their Modulation by a Triblock Polymer MST-188," will be presented as part of the Oral and Poster Abstracts Program on Sunday December 7, 2014 in Session 321: Blood Coagulation and Fibrinolytic Factors: Poster II, from 6:00-8:00pm PST in the Moscone Center, West Building, Level 1. In addition, the abstract has also been published in the November 14, 2014 supplemental volume of the journal Blood.
MSTX: 0.57 (+0.01)
Mast Therapeutics Announces Closing Of Underwritten Public Offering
PR Newswire - Thu Nov 13, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of equity securities. Gross proceeds from the offering were $21 million and the Company estimates net proceeds from the offering will be approximately $20 million, after deducting underwriting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds primarily to fund its clinical development programs, including EPIC, the Company's ongoing pivotal Phase 3 study of MST-188 in sickle cell disease, and for working capital and general corporate purposes.
MSTX: 0.57 (+0.01)
Mast Therapeutics Announces Pricing Of Underwritten Public Offering
PR Newswire - Thu Nov 06, 8:20AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering that is expected to raise gross proceeds of approximately $21 million.
MSTX: 0.57 (+0.01)
Mast Therapeutics Announces Underwritten Public Offering
PR Newswire - Wed Nov 05, 3:01PM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that it intends to offer and sell equity securities in an underwritten public offering. Cowen and Company, LLC is acting as sole book-running manager for the offering.
MSTX: 0.57 (+0.01)
Mast Therapeutics Reports Third Quarter 2014 Financial Results
PR Newswire - Fri Oct 31, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today reported financial results for the quarter ended September 30, 2014.
MSTX: 0.57 (+0.01)
Mast Therapeutics Announces Appointment Of Chief Medical Officer
PR Newswire - Thu Oct 02, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, announced today that Edwin L. Parsley, D.O. has joined the Company as its Chief Medical Officer and Senior Vice President.
MSTX: 0.57 (+0.01)
Mast Therapeutics Announces Positive Top Line Results From Phase 2 Study Of AIR001 For Pulmonary Arterial Hypertension And AIR001 Clinical Development Plan
PR Newswire - Mon Sep 08, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported top-line results from a Phase 2 study of AIR001 (sodium nitrite) inhalation solution for the treatment of pulmonary arterial hypertension (PAH). Mast obtained the rights to the AIR001 program through its acquisition of privately-held Aires Pharmaceuticals, Inc. earlier this year. In the primary efficacy analysis of the Phase 2 study, all doses showed improvement in median pulmonary vascular resistance (PVR). In the secondary efficacy analysis, all doses showed improvements in the median distances obtained in the 6-minute walk test, including clinically-meaningful improvements at the highest dose level. Additionally, AIR001 was well-tolerated, with no treatment related serious adverse events. In particular, methemoglobin levels remained normal (< 1.5%), which distinguishes AIR001 from safety concerns associated with intravenously-administered nitrite.
MSTX: 0.57 (+0.01)
Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th
PR Newswire - Tue Sep 02, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Rodman and Renshaw 16th Annual Global Investment Conference on Tuesday, September 9, 2014 at 2:55 p.m. Eastern time in the Holmes II Salon at The New York Palace Hotel in New York.
MSTX: 0.57 (+0.01)
Mast Therapeutics Announces Management Change
PR Newswire - Fri Aug 29, 3:05PM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX), an emerging biopharmaceutical company, announced today that Santosh Vetticaden, Chief Medical Officer and Senior Vice President, will be leaving the Company, for personal reasons, in mid-September. Edwin L. Parsley, D.O., the Chief Medical Officer of Aires Pharmaceuticals, which Mast acquired earlier this year, will assume Dr. Vetticaden's former responsibilities as the Company's interim Chief Medical Officer. Dr. Parsley previously was with Pfizer, where he oversaw clinical trials for Revatio® (sildenafil). He is a practicing physician and certified by the American Board of Internal Medicine in internal medicine, pulmonary disease, critical care medicine, and sleep medicine. Dr. Parsley has been actively engaged with the Company since Aires was acquired by Mast in February 2014.
MSTX: 0.57 (+0.01)
Mast Therapeutics Provides Corporate Update And Reports Second Quarter 2014 Financial Results
PR Newswire - Mon Aug 11, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today provided a corporate update and reported financial results for the quarter ended June 30, 2014.
MSTX: 0.57 (+0.01)
Technical Coverage on Biotech Stocks - Arena Pharma, XOMA, Dyax, Mast Therapeutics, and Tekmira Pharma
PR Newswire - Fri Jan 02, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), XOMA Corporation (NASDAQ: XOMA), Dyax Corporation (NASDAQ: DYAX), Mast Therapeutics Inc. (NYSE MKT: MSTX), and Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 31, 2014, the NASDAQ Composite ended at 4,736.05, down 0.87%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 17,823.07, and the S&P 500 closed at 2,058.90, down 1.03%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 791.97, down 0.98%, while the index has advanced 7.03% in the previous three months. Register for your complimentary reports on these five stocks at:
MSTX: 0.57 (+0.01), TKMR: 14.76 (-0.39), ARNA: 3.59 (+0.12), DYAX: 14.11 (+0.05), XOMA: 3.55 (-0.04)
Wall St. Deal Watch: New Research on VSE, Alexion, LCNB Corp., Lime Energy and Mast Therapeutics
PR Newswire - Fri Jan 02, 7:30AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including VSE (NASDAQ: VSEC), Alexion (NASDAQ: ALXN), LCNB Corp. (NASDAQ: LCNB), Lime Energy (NASDAQ: LIME), and Mast Therapeutics (NYSEMKT: MSTX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
VSEC: 68.58 (+2.68), MSTX: 0.57 (+0.01), LCNB: 14.87 (-0.20), LIME: 2.89 (-0.04), ALXN: 186.60 (+1.57)
Mast Therapeutics To Host Corporate Conference Call
PR Newswire - Tue Dec 30, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that it will hold a conference call at 8am Eastern Time, 5am Pacific Time on Tuesday, January 6, 2015. The Company intends to provide an update on EPIC, its pivotal phase 3 study of its lead product candidate vepoloxamer (MST-188) in sickle cell disease, which the Company continues to expect will complete enrollment by the end of 2015, and anticipated clinical and business milestones for 2015.
MSTX: 0.57 (+0.01)
Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/znzbgg/congestive_heart) has announced the addition of the "Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - Aastrom Biosciences - Johnson & Johnson - AstraZeneca - Athersys - GlaxoSmithKline - Gilead Sciences - Merck & Co - Bioheart - Neurocrine Biosciences - Acorda Therapeutics - Les Laboratoires Servier - Bayer - Celladon - IntelGenx - Mesoblast - Palatin Technologies - Cardio3 BioSciences - La Jolla Pharmaceutical - Mast Therapeutics - NeoStem - Cytomedix - Torrent Pharmaceuticals - Juventas Therapeutics - Protemix Corporation - AngioDesign - Cardioxyl Pharmaceuticals - Innopharmax - QUANTUM GENOMICS - ARCA biopharma For more information visit http://www.researchandmarkets.com/research/zn...tive_heart
JNJ: 104.52 (-0.05), NBIX: 22.84 (+0.50), MSTX: 0.57 (+0.01), GILD: 94.91 (+0.65), MRK: 57.19 (+0.40), PTN: 0.80 (+0.07), GSK: 42.37 (-0.37), BMY: 59.51 (+0.48), ACOR: 40.51 (-0.36)
Mast Announces Plans For Development Of Vepoloxamer (MST-188) In Heart Failure
PR Newswire - Tue Dec 09, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today provided details of its plan to develop vepoloxamer (MST-188), its lead product candidate, in heart failure.
MSTX: 0.57 (+0.01)
Actelion submits MAA for pulmonary hypertension drug
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 2:36PM CST
MSTX: 0.57 (+0.01), GILD: 94.91 (+0.65), UTHR: 127.73 (-1.76), GSK: 42.37 (-0.37), ARNA: 3.59 (+0.12)
Technical Snapshot on Biotech Stocks - Keryx Biopharma, Dyax, Mast Therapeutics, Cubist Pharma, and Intrexon
PR Newswire - Mon Dec 01, 7:30AM CST
Investor-Edge has initiated coverage on the following equities: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Dyax Corporation (NASDAQ: DYAX), Mast Therapeutics Inc. (NYSE MKT: MSTX), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and Intrexon Corporation (NYSE: XON). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, November 28, 2014, the NASDAQ Composite ended at 4,791.63, up 0.09%, the Dow Jones Industrial Average finished the day flat at 17,828.24, and the S&P 500 closed at 2,067.56, down 0.25%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 803.65, up 0.58%, with the index also advancing 8.95% in the previous three months. Register for your complimentary reports on these five stocks at:
CBSTZ: 0.06 (+0.02), MSTX: 0.57 (+0.01), CBST: 100.76 (+0.11), XON: 26.11 (-1.42), DYAX: 14.11 (+0.05), KERX: 14.34 (+0.19)
Mast Therapeutics To Present At The 26th Annual Piper Jaffray Healthcare Conference On December 3rd
PR Newswire - Wed Nov 26, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the 26th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 9:00 a.m. Eastern time in the Rutherford Salon at The New York Palace Hotel in New York City.
MSTX: 0.57 (+0.01)
Highline Research Advisors Initiates on Mast Therapeutics with a Buy Rating
Thomson Reuters ONE - Wed Nov 19, 12:08PM CST
SAN FRANCISCO - November 19, 2014 - Highline Research Advisors, LLC, a Merriman Capital, Inc. Financial Entrepreneur Platform participant announced today that research analyst Michael Higgins has initiated equity research coverage of Mast Therapeutics (AMEX: MSTX) with a Buy rating and a $3.00 price target.
MSTX: 0.57 (+0.01)
New Data From Nonclinical Heart Failure Study To Be Presented At American Heart Association Conference
PR Newswire - Wed Nov 19, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that data from MST-188 (vepoloxamer), its lead product candidate, will be featured at the American Heart Association (AHA) Scientific Sessions 2014. Data will be presented as a poster during the session "Heart Failure Pharmacology: From the Membrane to the Mitochondria." The AHA conference is being held at the McCormick Place Convention Center in Chicago through November 19.
MSTX: 0.57 (+0.01)
Mast Therapeutics To Present MST-188 Data At 2014 American Society Of Hematology Conference
PR Newswire - Mon Nov 17, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that it will be presenting data from an ex vivo study of MST-188 (vepoloxamer), its lead product candidate, at the 56th Annual Meeting of the American Society of Hematology (ASH) taking place December 6 - 9, 2014 in San Francisco, California. The abstract entitled "Pro-coagulant Actions of Circulating Microparticles in Sickle Cell Anemia and Sepsis Associated Coagulopathy and their Modulation by a Triblock Polymer MST-188," will be presented as part of the Oral and Poster Abstracts Program on Sunday December 7, 2014 in Session 321: Blood Coagulation and Fibrinolytic Factors: Poster II, from 6:00-8:00pm PST in the Moscone Center, West Building, Level 1. In addition, the abstract has also been published in the November 14, 2014 supplemental volume of the journal Blood.
MSTX: 0.57 (+0.01)
Mast Therapeutics Announces Closing Of Underwritten Public Offering
PR Newswire - Thu Nov 13, 7:00AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of equity securities. Gross proceeds from the offering were $21 million and the Company estimates net proceeds from the offering will be approximately $20 million, after deducting underwriting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds primarily to fund its clinical development programs, including EPIC, the Company's ongoing pivotal Phase 3 study of MST-188 in sickle cell disease, and for working capital and general corporate purposes.
MSTX: 0.57 (+0.01)
Mast Therapeutics Announces Pricing Of Underwritten Public Offering
PR Newswire - Thu Nov 06, 8:20AM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering that is expected to raise gross proceeds of approximately $21 million.
MSTX: 0.57 (+0.01)
Mast Therapeutics Announces Underwritten Public Offering
PR Newswire - Wed Nov 05, 3:01PM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today announced that it intends to offer and sell equity securities in an underwritten public offering. Cowen and Company, LLC is acting as sole book-running manager for the offering.
MSTX: 0.57 (+0.01)
Mast Therapeutics Reports Third Quarter 2014 Financial Results
PR Newswire - Fri Oct 31, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today reported financial results for the quarter ended September 30, 2014.
MSTX: 0.57 (+0.01)
Mast Therapeutics Announces Appointment Of Chief Medical Officer
PR Newswire - Thu Oct 02, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, announced today that Edwin L. Parsley, D.O. has joined the Company as its Chief Medical Officer and Senior Vice President.
MSTX: 0.57 (+0.01)
Mast Therapeutics Announces Positive Top Line Results From Phase 2 Study Of AIR001 For Pulmonary Arterial Hypertension And AIR001 Clinical Development Plan
PR Newswire - Mon Sep 08, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported top-line results from a Phase 2 study of AIR001 (sodium nitrite) inhalation solution for the treatment of pulmonary arterial hypertension (PAH). Mast obtained the rights to the AIR001 program through its acquisition of privately-held Aires Pharmaceuticals, Inc. earlier this year. In the primary efficacy analysis of the Phase 2 study, all doses showed improvement in median pulmonary vascular resistance (PVR). In the secondary efficacy analysis, all doses showed improvements in the median distances obtained in the 6-minute walk test, including clinically-meaningful improvements at the highest dose level. Additionally, AIR001 was well-tolerated, with no treatment related serious adverse events. In particular, methemoglobin levels remained normal (< 1.5%), which distinguishes AIR001 from safety concerns associated with intravenously-administered nitrite.
MSTX: 0.57 (+0.01)
Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th
PR Newswire - Tue Sep 02, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Rodman and Renshaw 16th Annual Global Investment Conference on Tuesday, September 9, 2014 at 2:55 p.m. Eastern time in the Holmes II Salon at The New York Palace Hotel in New York.
MSTX: 0.57 (+0.01)
Mast Therapeutics Announces Management Change
PR Newswire - Fri Aug 29, 3:05PM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX), an emerging biopharmaceutical company, announced today that Santosh Vetticaden, Chief Medical Officer and Senior Vice President, will be leaving the Company, for personal reasons, in mid-September. Edwin L. Parsley, D.O., the Chief Medical Officer of Aires Pharmaceuticals, which Mast acquired earlier this year, will assume Dr. Vetticaden's former responsibilities as the Company's interim Chief Medical Officer. Dr. Parsley previously was with Pfizer, where he oversaw clinical trials for Revatio® (sildenafil). He is a practicing physician and certified by the American Board of Internal Medicine in internal medicine, pulmonary disease, critical care medicine, and sleep medicine. Dr. Parsley has been actively engaged with the Company since Aires was acquired by Mast in February 2014.
MSTX: 0.57 (+0.01)
Mast Therapeutics Provides Corporate Update And Reports Second Quarter 2014 Financial Results
PR Newswire - Mon Aug 11, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today provided a corporate update and reported financial results for the quarter ended June 30, 2014.
MSTX: 0.57 (+0.01)
